These drugs are used successfully to treat cancer have yielded promising results that can prevent and even reverse type 1 diabetes in those already diagnosed.

diabetes_actualidad

With the use of two drugs to treat cancer, a team of scientific researchers from the University of California at San Francisco succeeded in preventing the diagnosis of Type 1 diabetes in laboratory mice are highly susceptible to further develop and could reverse in 80% of mice that already had type 1 diabetes.

These drugs known as Gleevec ® (Imatinib) and Sutent ® (Sunitinib) inhibit tyrosine kinases and revealed by the research team, these drugs appear to block a receptor tyrosine kinase that hitherto unaware that it related directly to the diagnosis of Type 1 Diabetes.
Both Gleevec ® and Sutent ®, block tyrosine kinases, enzymes that are growth factor receptors, platelet-derived (PDGFR) that regulate growth and cell division and are also related to the inflammation process and system operation immune. Many researchers agree that tyrosine kinases also facilitate the development of cancer and other immunological diseases, so these researchers believed also played a role in the attack of immune system cells to beta cells (insulin producing) that is what causes the onset of type 1 diabetes.

How was this important study?
Dr. Jeffrey Bluestone, spokeswoman for the research team said that he and and his colleagues wondered whether these drugs may also block some of the kinases thyroxine assumed that they were directly related to the development of Type 1 Diabetes and immediately began to investigate.
The idea was to test these drugs in mice with high predisposition to developing Type 1 diabetes, which as everyone knows, is a disease of immune status. The results were surprising since these drugs prevented these mice develop type 1 diabetes.
Another step of this study was to use these drugs in mice that already had Type 1 diabetes and the results were even more promising, since 80% of these mice showed normal levels of glucose in the blood after only 8 to 10 weeks of treatment.
This showed that investigators were successful in their hypothesis that these drugs may block a receptor tyrosine kinase which was unknown who was closely involved in the development of type 1 diabetes.
Dr. Jeffrey Bluestone, concluded, “The fact that mice treated with these drugs maintain normal glucose levels in blood for some time after the treatment stopped, indicates that both Gleevec ® (imatinib) as Sutent ® (Sunitinib) could have rescheduled their immune systems permanently. ”
For his part, Dr. Teodora Staeva Ph.D. who is the director of Immunology Research Foundation Juvenile Diabetes (JDRF) said: “The results of this study suggest that kinase inhibitors may provide new therapies in the treatment of Type 1 diabetes and other diseases of immune status ”

One hope for the future
Type 1 diabetes, also known as Juvenile Diabetes and Diabetes Insulin is a enfermadad that occurs when immune cells destroy the beta cells are insulin producing cells, so that in this type of diabetes the pancreas does not produce insulin and people with Type 1 diabetes depend solely on the use of exogenous insulin for treatment, unlike people with type 2 diabetes have a large variety of medications and therapies available to control. So this important study is even much more important and certainly opens a huge window of optimism and hope to all those with Type 1 Diabetes.

Be Sociable, Share!